Steiner joins Security Health Plan as medical director

Security Health Plan of Wisconsin, Inc., has named Robert Steiner, M.D. medical director.

“We are very fortunate to have someone of Dr. Robert Steiner’s caliber join us as part of Health Management Services,” said Chief Medical Officer Eric Quivers, M.D.

“His training and experience in the field of medical genetics is of great value. He has worked in academia, research and clinical practice. Most recently, he has served as the Chief Medical Officer for Acer Therapeutics, a pharmaceutical company, and had oversight of the development of treatments for metabolic disorders. The use of genetic testing is a rapidly growing area in medicine. Its use has expanded beyond testing for inheritable conditions, which remains important, into areas such as the diagnosis and treatment of cancer. Dr. Steiner’s expertise in the field of medical genetics will help guide us at Security Health Plan as we seek to develop a well-thought-out approach to this rapidly expanding area in medicine. I see this as a huge positive for our members and the Marshfield Clinic Health System,” said Quivers.

Dr. Steiner is an alumnus of the University of Wisconsin - Madison and the University of Wisconsin - Madison Medical School. He has published extensively in peer-reviewed journals and been awarded more than $15 million in research grants. His past positions include executive director of the Marshfield Clinic Research Foundation, chief science officer of the Marshfield Clinic and chief medical officer of Acer Therapeutics. 

Dr. Steiner will assist Security Health Plan in the development of genetic testing policies and with complex genetic testing prior authorization determinations.  

“Genetic tests are often complex and not inexpensive tests – and it can be challenging to decide when they are medically necessary. But genetic tests play more and more of a role in clinical medicine these days; they are important for understanding patients’ health status in certain situations, and can be the first step to diagnosing them and managing potential genetic disease. Testing comes first, then treatment,” said Steiner.